Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBT (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of EBT data on record, last reported at -$40.8 million in Q3 2025.

  • For Q3 2025, EBT fell 60.44% year-over-year to -$40.8 million; the TTM value through Sep 2025 reached -$130.8 million, down 94.94%, while the annual FY2024 figure was -$84.5 million, 94.65% down from the prior year.
  • EBT reached -$40.8 million in Q3 2025 per DNTH's latest filing, down from -$32.6 million in the prior quarter.
  • Across five years, EBT topped out at -$7.1 million in Q1 2023 and bottomed at -$40.8 million in Q3 2025.
  • Average EBT over 4 years is -$19.9 million, with a median of -$17.3 million recorded in 2022.
  • Peak YoY movement for EBT: skyrocketed 69.16% in 2023, then plummeted 165.66% in 2024.
  • A 4-year view of EBT shows it stood at -$10.1 million in 2022, then fell by 4.57% to -$10.5 million in 2023, then tumbled by 165.66% to -$27.9 million in 2024, then tumbled by 46.24% to -$40.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$40.8 million in Q3 2025, -$32.6 million in Q2 2025, and -$29.4 million in Q1 2025.